Melflufen for relapsed and refractory multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21027J4" target="_blank" >RIV/61988987:17110/20:A21027J4 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/20:E0108606
Result on the web
<a href="https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1808884?needAccess=true" target="_blank" >https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1808884?needAccess=true</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/13543784.2020.1808884" target="_blank" >10.1080/13543784.2020.1808884</a>
Alternative languages
Result language
angličtina
Original language name
Melflufen for relapsed and refractory multiple myeloma
Original language description
Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. Patients with disease that is refractory to multiple novel agents represent a population with high unmet medical need and for whom therapies with new mechanisms of action could be beneficial. Melphalan flufenamide (melflufen) has demonstrated encouraging activity in patients with relapsed and refractory multiple myeloma. Areas covered: This review provides an overview of the mechanism of action of melflufen, a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly delivers alkylating agents into tumor cells. It reviews key Phase I and II clinical trial data for melflufen in combination with dexamethasone as well as in triplet combinations with daratumumab or bortezomib. The safety profile of melflufen, which is characterized primarily by clinically manageable hematologic adverse events, is described. Expert opinion: Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert Opinion on Investigational Drugs
ISSN
1354-3784
e-ISSN
—
Volume of the periodical
29
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
1069-1078
UT code for WoS article
000573668900001
EID of the result in the Scopus database
—